Government

$2.92M Investment by NCI Will Lead to Validated Clinical Cancer Diagnostic Algorithms Using Pathcore’s Technologies TORONTO -- Pathcore™ and a team of investigators from the US and Canada have received an award from the National...

Last week news was released after months of speculation, that the FDA would consider the de novo classification option for digital pathology systems as a pathway for bringing to market a moderate or low risk device which has not yet been...

Collaboration with FDA Results in Opportunity for Streamlined Approval Process The Digital Pathology Association (DPA) announced today that it suggests digital pathology manufacturers currently interested in marketing whole slide imaging (WSI)...

I don’t usually make political statements on this blog and don’t plan on doing so anytime soon. In fact, I have little interest at the moment and 2-year presidential election cycles and endless coverage of every detail of the professional...

Click on the image below to register. Members may register for free at www.digitalpathologyassociation.org. Non-member fee is $100. Source: Digital Pathology...

Since the inception of commercially available whole slide imaging systems more than 15 years ago, a necessary requirement has been to prove that diagnoses made using DP alone are equal to or better than conventional glass slides (GS) that have...